Skip to main content

Table 1 Elite Controller Study Population Characteristics.

From: T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers

Subject ID Gender1 Age2 CD43 CD83 Duration of infection2 %CD38+DR+CD8+ Duration CD4 FUP/VL control2,3 #CD4 assessments Annual Rate of CD4 decline4
EC 1 M 37 680 680 1 14.60 2.91 8 9.4 (-55.9,74.8)
EC 2 M 31 715 384 5 5.42 5.14 11 -17.7 (-56.2,20.8)
EC 3 M 68 660 1082 4 3.59 5.16 17 6.19 (-14.5,26.7)
EC 4 F 58 714 714 4 4.68 5.77 14 -6.73 (-50.7,37.2)
EC 5 M 53 310 730 6 3.95 5.27 14 -52.6 (-76.6,28.5)
EC 6 F 46 720 631 11 6.63 8.75 25 -7.4 (-22.7,8.0)
EC 7 M 37 1040 1095 11 4.33 9.64 22 14.4 (-6.5,35.3)
EC 8 F 40 737 303 12 7.11 12.08/14.52 22 -44.2 (-58.0,-30,4)
EC 9 M 53 800 288 10 7.35 14.88 35 15.9 (10.3,21.6)
EC 10 M 45 1050 1296 20 7.41 12.27 22 -11.2 (-27.9,5.4)
EC 11 M 39 689 455 9 10.20 16.78/9.12 86 -48.9 (-59.2,-38.6)
EC 12 F 33 728 434 10 2.36 17.30 79 -49.2 (-53.4,-45.0)
EC 13 M 47 770 1130 19 12.70 20.02/21.63 17 -33.0 (-50.6,-15.3)
EC 14 M 31 928 1566 2 20.00 2.75 N.A. N.A.5
EC 15 F 31 442 816 2 12.40 4.75 4 15.8 (-19.3,50.9)
EC 16 F 60 800 1026 13 3.00 13.64 8 -5.3 (-58,7,58.0)
EC 17 M 40 460 307 4 6.35 3.87 10 4.3 (-40.9,49.6)
EC 18 M 42 870 551 1 8.27 1.50 N.A. N.A.
EC 19 F 30 692 627 6 10.10 2.17 6 -17.0 (-121.5,87.5)
EC 20 F 40 576 498 12 20.20 15.18/15.73 13 -30.9 (-50.2,-11.7)
EC 21 M 36 343 804 14 12.20 1.05 N.A. N.A.
EC 22 M 61 670 540 4 12.5 4.62 11 32.1 (-27.3,91.5)
EC 23 M 53 740 820 11 33.2 18.01 16 -15.1 (-33.3,3.0)
EC 24 M 41 978 787 1 37.3 11.24 29 -16.0 (-27.6,-4.4)
EC 25 M 55 990 680 10 15.3 9.48 16 -29.0 (-70.5, 12.5)
EC 26 M 68 970 400 17 17.5 13.18 19 14.5 (3.8,25.2)
EC 27 M 41 1200 860 11 13.9 12.39 34 28.6 (7.4,49.7)
EC 28 M 48 700 920 8 35.4 17.20 35 -1.4 (-5.0,2.1)
EC 29 F 53 499 202 8 28.9 N.A. N.A. N.A.
EC 30 M 40 510 1286 14 21.5 N.A. N.A. N.A.
EC 31 F 47 485 277 20 17.3 N.A. N.A. N.A.
EC 32 F 56 865 388 15 20.7 N.A. N.A. N.A.
EC 33 F 56 1488 1012 17 2.39 N.A. N.A. N.A.
EC 34 M 56 801 713 18 20.7 N.A. N.A. N.A.
  1. 1M = male;F = female
  2. 2 years.
  3. 3The duration of CD4 follow up/duration of viral load control if different from duration of CD4 follow up.
  4. 4 cells/mm3 (95% confidence intervals).
  5. 5 Not available (insufficient information available to calculate a slope of CD4 counts change).